Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Treatment Outcome Priorities of Older Adults with Newly Diagnosed Blood Cancers Elicited with Best-Worst Scaling

Daniel R. Richardson, Carl J. Mhina, Matthew Washko, Allison M Deal, Amy C. Cole, Mattias Jonsson, Stephanie B Wheeler, Norah L Crossnohere, John F.P. Bridges

Blood (2023) 142 (Supplement 1): 2334.

https://doi.org/10.1182/blood-2023-182076

Published: 2023

Journal Articles

Patient Values, Information Preferences, and Decisional Preferences Among Older Adults with Acute Myeloid Leukemia

Kah Poh (Melissa) Loh, Soroush Mortaz-Hedjri, Ying Wang, Marissa Locastro, Sally Norton, Jason H. Mendler, Jane L. Liesveld, Eric J Huselton, Marielle Jensen-Battaglia, Kathryn Buettner, Jenae Davis, Heidi Klepin, Daniel R. Richardson

Blood (2023) 142 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2023-172827

Published: 2023

Journal Articles

Patient Preference Studies in Hematologic Malignancies: A Systematic Review

Daniel R. Richardson, Matthew Washko, Konan Beke, Marissa Locastro, Nicola Campoamor, Carl J. Mhina, Norah L Crossnohere, John F.P. Bridges

Blood (2023) 142 (Supplement 1): 7241.

https://doi.org/10.1182/blood-2023-178754

Published: 2023

Journal Articles

A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study

Marissa Locastro, Chandrika Sanapala, Ying Wang, Marielle Jensen-Battaglia, Marsha Wittink, Sally Norton, Heidi Klepin, Daniel R. Richardson, Jason H. Mendler, Jane L. Liesveld, Eric J. Huselton, Kristen M. O'Dwyer, Ashley-Marie Cortes, Chrystina Rodriguez, Kah Poh (melissa) Loh

Blood (2022) 140 (Supplement 1): 324–325.

https://doi.org/10.1182/blood-2022-165499

Published: 2022

Journal Articles

Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Ya-Ning Chan, Daniel R. Richardson, Courtney Berry, Stephanie Betancur, Hayden Michael Dumaw, Todd Schwartz, Mackenzi Pergolotti, Susan Coppola, Christopher Jensen, Matthew C. Foster, Ashley L. Bryant

Blood (2022) 140 (Supplement 1): 9074–9075.

https://doi.org/10.1182/blood-2022-166419

Published: 2022

Journal Articles

Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Antonia V. Bennett, Xianming Tan, Matthew C. Foster, Daniel R. Richardson, Ashley L. Bryant, William A. Wood, Jr., Ashley O. Yocum, Alice S. Mims, Uma Borate, Amy Burd

Blood (2022) 140 (Supplement 1): 3367–3368.

https://doi.org/10.1182/blood-2022-160426

Published: 2022

Journal Articles

Distance to Treatment Center Is Associated with Health Outcomes in Older Adults with AML Receiving Azacitidine and Venetoclax Containing Regimens

Konan E. Beke, Hillary M. Heiling, Christopher E. Jensen, Allison M. Deal, Daniel R. Richardson

Blood (2021) 138 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2021-146859

Published: 2021

Journal Articles

Time Spent at Home Among Older Adults with AML Treated with Hypomethylating Agents and Venetoclax

Christopher E. Jensen, Hillary M. Heiling, Konan E. Beke, Allison M. Deal, Ashley Leak Bryant, Lorinda Adaire Coombs, Matthew C. Foster, Daniel R. Richardson

Blood (2021) 138 (Supplement 1): 281.

https://doi.org/10.1182/blood-2021-144818

Published: 2021

Journal Articles

Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia

Steven M. Johnson, Lori Ramkissoon, James Haberberger, Naomi L Ferguson, Jonathan Galeotti, Daniel R. Richardson, Matthew C. Foster, Jeffrey Ross, Shakti H. Ramkissoon, Joshua F. Zeidner, Daniel Duncan, Nathan Montgomery

Blood (2021) 138 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2021-151796

Published: 2021

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Norah Crossnohere, MPH, Daniel R. Richardson, MD MA, B. Douglas Smith, MD, Crystal Reinhart, Bernadette O'Donoghue, Susan Love, MD MBA, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2018-99-116931

Published: 2018

Journal Articles

Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling

Daniel R. Richardson, MD MA, Allison H. Oakes, Gary Rathsmill, Crystal Reinhart, Bernadette O'Donoghue, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 717.

https://doi.org/10.1182/blood-2018-99-116669

Published: 2018

Journal Articles

Quantifying Patient Preferences for Treatment Outcomes in AML: A Discrete-Choice Experiment

Daniel R. Richardson, MD MA, Jaein Seo, PharmD, B. Douglas Smith, MD, Elihu H. Estey, MD, Bernadette O'Donoghue, John F.P. Bridges, PhD

Blood (2018) 132 (Supplement 1): 718.

https://doi.org/10.1182/blood-2018-99-113071

Published: 2018

Journal Articles

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Daniel R Richardson, MD, Qiuhong Zhao, MS, Rhonda Kitzler, MS, Patrick Elder, MS, Gerard Lozanski, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Sam Penza, MD, Sumithra Vasu, MBBS, Steven M Devine, MD

Blood (2016) 128 (22): 4598.

https://doi.org/10.1182/blood.V128.22.4598.4598

Published: 2016

Journal Articles

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Daniel R Richardson, MD, Ying Huang, MA, MS, Patrick Elder, MS, Joanna Newlin, LISW, Cyndi Kirkendall, LISW, Steven M Devine, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Craig C Hofmeister, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Heather L McGinty, PhD, Sam Penza, MD, Sumithra Vasu, MBBS, Basem M William, MD, Ashley E Rosko, MD

Blood (2016) 128 (22): 1241.

https://doi.org/10.1182/blood.V128.22.1241.1241

Published: 2016

NARROW

Treatment Outcome Priorities of Older Adults with Newly Diagnosed Blood Cancers Elicited with Best-Worst Scaling

Patient Values, Information Preferences, and Decisional Preferences Among Older Adults with Acute Myeloid Leukemia

Patient Preference Studies in Hematologic Malignancies: A Systematic Review

A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study

Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Distance to Treatment Center Is Associated with Health Outcomes in Older Adults with AML Receiving Azacitidine and Venetoclax Containing Regimens

Time Spent at Home Among Older Adults with AML Treated with Hypomethylating Agents and Venetoclax

Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Understanding the Collateral Damage of Treating Acute Myeloid Leukemia: An Estimate of Patient-Reported Side Effect Rates from a National Survey

Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling

Quantifying Patient Preferences for Treatment Outcomes in AML: A Discrete-Choice Experiment

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only